Altek Business Summary

Altek Corporation (3059.TW) is a premier provider of imaging technology and AI vision solutions, having successfully transitioned from a global top-three digital camera manufacturer into a high-value provider of Edge Vision AI, medical imaging, and automotive sensing systems. The company generates revenue through a diversified mix of hardware sales, custom ASIC/ISP chip design, and comprehensive CDMO (Contract Development and Manufacturing Organization) services for the healthcare sector. Its primary business segments include AI Vision (3D sensing and AIoT cameras), Medical Imaging (disposable endoscopes and diabetes care devices such as insulin pumps), and Automotive Solutions (ADAS and surround-view camera modules). For the fiscal year ended December 31, 2025, Altek reported consolidated revenue of TWD 8.68 billion, representing a 20.6% year-over-year increase. The company competes primarily with Ability Enterprise Co., Ltd., Asia Optical Co., Inc., and Largan Precision, positioning itself as a specialized niche leader in high-precision medical-grade imaging and integrated AI-on-chip solutions rather than mass-market consumer optics. Altek was founded in 1996 by current Chairman and CEO Alex Hsia (Ju Wen Hsia), a veteran of the imaging industry who previously served as Vice President of Microtek and holds an M.A. in Electronics Engineering from the University of California, Santa Barbara. The leadership team includes Senior VP and CFO Belle Liang (Min Fang Liang), who brings extensive financial expertise from her tenure at Taiwan High Speed Rail Corporation, and Spokesperson Steven Chen. The Board of Directors is bolstered by high-pedigree independent members, including Mori Shorei, a former researcher at the University of Tokyo and director at Fuji Film Japan, and Michael Ding, a Ph.D. in Economics from Indiana University. Notable institutional backing is provided by major global investment firms, including The Vanguard Group, Dimensional Fund Advisors, and State Street Global Advisors, reflecting the company’s stable governance and strategic pivot toward the AI and MedTech sectors.